Rhythm Pharmaceuticals, Inc. (RYTM)

From the record

Rhythm Pharmaceuticals, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Rhythm Pharmaceuticals, Inc.'s 5 filed years say what it did: revenue went from $3 million in fiscal 2021 to $190 million in fiscal 2025, up 178.5% a year; it rose in 4 of 4 years; it never fell from a peak; net income was positive in 0 of 5 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Rhythm Pharmaceuticals, Inc. lost about 141 cents for every dollar of shareholders' money, and gross profitability: its products earned about 35 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 71 cents per dollar of assets, and net share issuance: its share count grew 6.5% over the year (the filed statements).

From the record

Rhythm Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $190 million in fiscal 2025 ranks in the top 29% by size; a net margin of -103.6% ranks in the top 47%; revenue growth of 100.2% a year over the last 3 filed years ranks in the top 13% (its annual reports).

From the record

Rhythm Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Meeker, David P (President and CEO, as filed), filing under that title since 2020-07-21, 6.3 years (top 35% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 6.1 years (top 40%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 8%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Rhythm Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $54 million against debt of $101 million leaves -9.7% of its assets as net cash, bottom 10% of its family; cash from operations less capital spending is -61.5% of revenue (top 46%); a gross margin of 89.7% (top 14%); research spending of 88.2% of revenue (bottom 47%) (its annual report).

From the record

Rhythm Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 100.2% a year over the last three filed years against 178.5% over all 5, slowing (bottom 7% of its family); the newest year grew 45.9% (top 27%); research spending grew 15.5% a year (top 30%); capital spending grew 50.2% a year (top 14%) (its annual reports). Rhythm Pharmaceuticals, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Rhythm Pharmaceuticals, Inc.'s newest year against its own record: revenue of $190 million in fiscal 2025 came in 37.8% below the $305 million its prior three years' pace pointed to (bottom 24% of its family); net income of $197 million against a prior three-year average of $209 million (bottom 44%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 24%) (its annual reports).